High Time
Colorado Cannabis Company to Study Cannabinoids Effect on Alzheimer’s Disease
News by Thomas Edward on February 28, 2020
Cannabis believes it has less impact on young minds than once believed, study says
A Colorado company is aiming to be the first to investigate the effects of marijuana on Alzheimer’s disease.

The Denver Post reported that Medpharm Religion intended to apply for a research and development license to test the effects of “delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD), and other cannabinoids on Alzheimer’s and dementia patients.” “

advertisement

Denver-based MedPharm CEO Albert Gutierrez told the newspaper that research on cannabis’ ability to treat Alzheimer’s is largely unexplored.

The Denver Post said, “We have not yet taken into account what this plant can help reduce symptoms.” “We hear a lot of important evidence so far as helping with epilepsy or arthritis pain … now is the time to put cannabinoids to the test and really understand what cannabinoids and what dosage and Does the delivery methods really help give that relief. “

According to the Post, Colorado lawmakers introduced research and development licensing in 2017 with the passage of House Bill 1367, but left it to the municipalities to decide individually whether they would introduce it. According to the Marijuana Enforcement Division, only one company – MedPharm – has so far applied for an R&D license. “

Cannabis use and senior
Cannabis research has been hamstrung by the fact that pot is illegal at the federal level, but that has not stopped many from advancing weed-related discoveries in the science and medical community – particularly its impact on patients. Thorsten Rudroff, a professor in the Department of Neurology at the University of Iowa’s Carver College of Medicine, is currently seeking volunteers between the ages of 50 and 80 who participate in a study about whether cannabis use poses a greater risk in their falls. Does it or not.

The study will include two pools of individuals: those who use marijuana, and those who do not. For Rudraoff, this is an opportunity to investigate the use of pot among a group of people who might not be equipped with dumbbells.

“It is self-medicating,” said Rudroff. “They have no idea how medical cannabis is used. There are no guidelines, no recommendations. We want to find out which is the best and safest product. “

A study published earlier this month in the journal JAMA Internal Medicine found that cannabis use among seniors jumped dramatically by 75 percent over the past three years.